Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports

Abrams, 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer, Mol Cancer Ther, 2, 471 Kim, 2006, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases, J Clin Endocrinol Metab, 91, 4070, 10.1210/jc.2005-2845 Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327 Murray, 2003, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model, Clin Exp Metastasis, 20, 757, 10.1023/B:CLIN.0000006873.65590.68 O’Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, 101, 3597, 10.1182/blood-2002-07-2307 Trinh, 2007, Sunitinib relieves renal cell carcinoma spinal cord compression, Eur Urol, 51, 1741, 10.1016/j.eururo.2006.10.050 Sutent, summary of product characteristics. New York, NY: Pfizer Inc; 2008. Ficarra, 2008, Risk stratification and prognostication of renal cell carcinoma, World J Urol, 26, 115, 10.1007/s00345-008-0259-y Karakiewicz, 2007, Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival, Eur Urol, 51, 1616, 10.1016/j.eururo.2006.12.015 Frank, 2002, An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score, J Urol, 168, 2395, 10.1016/S0022-5347(05)64153-5 Leibovich, 2003, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials, Cancer, 97, 1663, 10.1002/cncr.11234 Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.20.1.289 Ljungberg, 2007, Renal cell carcinoma guideline, Eur Urol, 51, 1502, 10.1016/j.eururo.2007.03.035 Gore, 2007, Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded open access trial with subpopulation analysis, J Clin Oncol, 25, 237S, 10.1200/jco.2007.25.18_suppl.5010